Scott Braunstein, Marinus Pharmaceuticals CEO

Mar­i­nus re­ports mixed Phase 3 re­sults on IV seizure drug

Mar­i­nus Phar­ma­ceu­ti­cals re­port­ed Mon­day that its IV drug met on­ly one of two key end­points in a Phase 3 study for pro­longed seizures.

In the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.